West Nyack, New York Clinical Trials
A listing of West Nyack, New York clinical trials actively recruiting patient volunteers.
Found 33 clinical trials
Second Primary Lung Cancer Cohort Study (SPORT) (SPORT)
Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further …
- 0 views
- 12 Feb, 2026
- 1 location
- Online study
Prevalence of Subacromial Impingement Among Egyptian Swimmers : A Cross Sectional Survey Study.
In the available literature, there are no prevalence studies that show the incidence of subacromial impingement in swimmers in Egypt, this should be considered as it's one of the most commonly reported injuries worldwide in swimmers. There are also no available studies to show the difference in incidence of subacromial …
- 0 views
- 22 Sep, 2022
- 1 location
- Online study
Prevalence of Subacromial Impingement Among Egyptian Swimmers : A Cross Sectional Survey Study.
In the available literature, there are no prevalence studies that show the incidence of subacromial impingement in swimmers in Egypt, this should be considered as it's one of the most commonly reported injuries worldwide in swimmers. There are also no available studies to show the difference in incidence of subacromial …
- 0 views
- 22 Sep, 2022
- 1 location
- Online study
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
- 32 views
- 16 Feb, 2024
- +126 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
- 0 views
- 16 Feb, 2024
- +210 other locations
Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their cancer. The Quad Shot treatment schedule reduces the number of days needed …
- 0 views
- 16 Feb, 2024
- +6 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study
This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …
- 0 views
- 16 Feb, 2024
- +358 other locations
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find …
- 0 views
- 16 Feb, 2024
- +6 other locations
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see …
- 0 views
- 16 Feb, 2024
- +9 other locations